These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis. Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406 [TBL] [Abstract][Full Text] [Related]
6. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764 [TBL] [Abstract][Full Text] [Related]
7. [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012 [TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
10. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. Todeschini G; Ambrosetti A; Meneghini V; Pizzolo G; Menestrina F; Chilosi M; Benedetti F; Veneri D; Cetto GL; Perona G J Clin Oncol; 1990 May; 8(5):804-8. PubMed ID: 1692089 [TBL] [Abstract][Full Text] [Related]
11. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma. Todd M; Cadman E; Spiro P; Bertino J; Farber L; Waldron J; Fischer D J Clin Oncol; 1984 Sep; 2(9):986-93. PubMed ID: 6206207 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol]. Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405 [TBL] [Abstract][Full Text] [Related]
13. A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma. Lee R; Cabanillas F; Bodey GP; Freireich EJ J Clin Oncol; 1986 Oct; 4(10):1455-61. PubMed ID: 2428947 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226 [TBL] [Abstract][Full Text] [Related]
15. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144 [TBL] [Abstract][Full Text] [Related]
16. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. Dana BW; Dahlberg S; Miller TP; Hartsock RJ; Balcerzak S; Coltman CA; Carden JO; Hartley K; Fisher RI J Clin Oncol; 1990 Jul; 8(7):1155-62. PubMed ID: 1694233 [TBL] [Abstract][Full Text] [Related]
17. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood. Maluf PT; Odone Filho V; Cristofani LM; Britto JL; Almeida MT; Pontes E; Maksoud JG; Manissadjian A J Clin Oncol; 1994 Sep; 12(9):1963-8. PubMed ID: 8083717 [TBL] [Abstract][Full Text] [Related]
18. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814 [TBL] [Abstract][Full Text] [Related]
20. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. Patte C; Philip T; Rodary C; Zucker JM; Behrendt H; Gentet JC; Lamagnère JP; Otten J; Dufillot D; Pein F J Clin Oncol; 1991 Jan; 9(1):123-32. PubMed ID: 1985161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]